[1]
Polgár, L. The prolyl oligopeptidase family. Cell. Mol. Life Sci., 2002, 59(2), 349-362.
[2]
Brocca, S.; Ferrari, C.; Barbiroli, A.; Pesce, A.; Lotti, M.; Nardini, M. A bacterial acyl aminoacyl peptidase couples flexibility and stability as a result of cold adaptation. FEBS J., 2016, 283(23), 4310-4324.
[3]
Szeltner, Z.; Rea, D.; Juhász, T.; Renner, V.; Mucsi, Z.; Orosz, G.; Fülöp, V.; Polgár, L. Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase. J. Biol. Chem., 2002, 277(47), 44597-44605.
[4]
Morty, R.E.; Pellé, R.; Vadász, I.; Uzcanga, G.L.; Seeger, W.; Bubis, J. Oligopeptidase B from Trypanosoma evansi. A parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected hosts. J. Biol. Chem., 2005, 280(12), 10925-10937.
[5]
Harmat, V.; Domokos, K.; Menyhárd, D.K.; Palló, A.; Szeltner, Z.; Szamosi, I.; Beke-Somfai, T.; Náray-Szabó, G.; Polgár, L. Structure and catalysis of acylaminoacyl peptidase: closed and open subunits of a dimer oligopeptidase. J. Biol. Chem., 2011, 286(3), 1987-98.
[6]
Hiramatsu, H.; Kyono, K.; Higashiyama, Y.; Fukushima, C.; Shima, H.; Sugiyama, S.; Inaka, K.; Yamamoto, A.; Shimizu, R. The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold., Biochem. Biophys.
Res. Commun., 2003, 302(4), 849-854.e.
[7]
Rawlings, N.D.; Barrett, A.J.; Thomas, P.D.; Huang, X.; Bateman, A.; Finn, R.D. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res., 2018, 46, D624-D632.
[8]
Maes, M.; Goossens, F.; Scharpé, S.; Meltzer, H.Y.; D’Hondt, P.; Cosyns, P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol. Psychiatry, 1994, 35(8), 545-552.
[9]
Maes, M.; Goossens, F.; Scharpé, S.; Calabrese, J.; Desnyder, R.; Meltzer, H.Y. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res., 1995, 58(3), 217-225.
[10]
Maes, M.; Monteleone, P.; Bencivenga, R.; Goossens, F.; Maj, M.; van West, D.; Bosmans, E.; Scharpe, S. Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology, 2001, 26(1), 17-26.
[11]
Männistö, P.T.; García-Horsman, A.J. Mechanism of action of prolyl oligopeptidase (PREP) in degenerative brain diseases: has peptidase activity only a modulatory role on the interactions of PREP with proteins? Front. Aging Neurosci., 2017, 9, 27.
[12]
Guardiola, S.; Prades, R.; Mendieta, L.; Brouwer, A.J.; Streefkerk, J.; Nevola, L.; Tarragó, T.; Liskamp, R.M.J.; Giralt, E. Targeted covalent inhibition of prolyl oligopeptidase (POP): Discovery of sulfonylfluoride peptidomimetics. Cell Chem. Biol., 2018, 25(8), 1031-1037.e4.
[13]
Morty, R.E.; Pellé, R.; Vadász, I.; Uzcanga, G.L.; Seeger, W.; Bubis, J. Oligopeptidase B from Trypanosoma evansi. A parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected hosts. J. Biol. Chem., 2005, 280(12), 10925-10937.
[14]
Swenerton, R.K.; Zhang, S.; Sajid, M.; Medzihradszky, K.F.; Craik, C.S.; Kelly, B.L.; McKerrow, J.H. The oligopeptidase B of Leishmania regulates parasite enolase and immune evasion. J. Biol. Chem., 2011, 286(1), 429-440.
[15]
Kim, N.H.; Yu, T.; Lee, D.H. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors. Biomed Res. Int., 2014, 2014368703
[16]
Nathan, D.M. Finding new treatments for diabetes--how many, how fast... how good? N. Engl. J. Med., 2007, 356(5), 437-440.
[17]
Russell, S. Incretin-based therapies for type 2 diabetes mellitus: A review of direct comparisons of efficacy, safety and patient satisfaction. Int. J. Clin. Pharm., 2013, 35(2), 159-172.
[18]
Röhrborn, D.; Wronkowitz, N.; Eckel, J. DPP4 in diabetes. Front. Immunol., 2015, 6, 386.
[19]
Avogaro, A.; Fadini, G.P. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care, 2014, 37(10), 2884-2894.
[20]
Aertgeerts, K.; Levin, I.; Shi, L.; Snell, G.P.; Jennings, A.; Prasad, G.S.; Zhang, Y.; Kraus, M.L.; Salakian, S.; Sridhar, V.; Wijnands, R.; Tennant, M.G. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J. Biol. Chem., 2005, 280(20), 19441-19444.
[21]
Kin, Y.; Misumi, Y.; Ikehara, Y. Biosynthesis and characterization of the brain specific membrane protein DPPX, a dipeptidyl peptidase IV-related protein. J. Biochem., 2001, 129, 289-295.
[22]
Strop, P.; Bankovich, A.J.; Hansen, K.C.; Garcia, K.C.; Brunger, A.T. Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family. J. Mol. Biol., 2004, 343(4), 1055-1065.
[23]
Ross, B.; Krapp, S.; Augustin, M.; Kierfersauer, R.; Arciniega, M.; Geiss-Friedlander, R.; Huber, R. Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer. Proc. Natl. Acad. Sci. USA, 2018, 115(7), E1437-E1445.
[24]
Bezerra, G.A.; Dobrovetsky, E.; Seitova, A.; Fedosyuk, S.; Dhe-Paganon, S.; Gruber, K. Structure of human dipeptidyl peptidase 10 (DPPY): A modulator of neuronal Kv4 channels. Sci. Rep., 2015, 5, 8769.
[25]
Yamada, R.; Ymamoto, K. Recent findings on genes associated with inflammatory disease. Mutat. Res., 2005, 573(1-2), 136-151.
[26]
Waumans, Y.; Baerts, L.; Kehoe, K.; Lambeir, A.M.; De Meester, I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front. Immunol., 2015, 6, 387.
[27]
Wagner, L.; Klemann, C.; Stephan, M.; von Hörsten, S. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin. Exp. Immunol., 2016, 184(3), 265-283.
[28]
Banbula, A.; Mak, P.; Bugni, M.; Silberring, J.; Dubin, A.; Nelson, D.; Travis, J.; Potempa, J. Prolyl tripeptidyl peptidase from Porphyromonas gingivalis - A novel enzyme with possible pathological implications for the development of periodontitis. J. Biol. Chem., 1999, 274(14), 9246-9252.
[29]
Xu, Y.; Nakajima, Y.; Ito, K.; Zheng, H.; Oyama, H.; Heiser, U.; Hoffmann, T.; Gartner, U.T.; Demuth, H.U.; Yoshimoto, T. Novel inhibitor for prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis and details of substrate-recognition mechanism. J. Mol. Biol., 2008, 375(3), 708-719.
[30]
Griffen, A.L.; Becker, M.R.; Lyons, S.R.; Moeschberger, M.L.; Leys, E.J. Prevalence of Porphyromonas gingivalis and periodontal health status. J. Clin. Microbiol., 1998, 36(11), 3239-3242.
[31]
Iwai, T.; Inoue, Y.; Umeda, M.; Huang, Y.; Kurihara, N.; Koike, M.; Ishikawa, I. Oral bacteria in the occluded arteries of patients with Buerger disease. J. Vasc. Surg., 2005, 42(1), 107-115.
[32]
Kshirsagar, A.V.; Offenbacher, S.; Moss, K.L.; Barros, S.P.; Beck, J.D. Antibodies to periodontal organisms are associated with decreased kidney function. The dental atherosclerosis risk in communities study. Blood Purif., 2007, 25(1), 125-132.
[33]
Detert, J.; Pischon, N.; Burmester, G.R.; and Buttgereit, F. The association between rheumatoid arthritis and periodontal disease. Arthritis Res. Ther., 2010, 12(5), 218.
[34]
Yamin, R.; Zhao, C.; O’Connor, P.B.; McKee, A.C.; Abraham, C.R. Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide. Mol. Neurodegener., 2009, 4, 33.
[35]
Palmieri, G.; Bergamo, P.; Luini, A.; Ruvo, M.; Gogliettino, M.; Langella, E.; Saviano, M.; Hegde, R.N.; Sandomenico, A.; Rossi, M. Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation. PLoS One, 2011, 6(10)e25888
[36]
Shimizu, K.; Kiuchi, Y.; Ando, K.; Hayakawa, M.; Kikugawa, K. Coordination of oxidized protein hydrolase and the proteasome in the clearance of cytotoxic denatured proteins. Biochem. Biophys. Res. Commun., 2004, 324(1), 140-146.
[37]
Perrier, J.; Durand, A.; Giardina, T.; Puigserver, A. Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie, 2005, 87(8), 673-685.
[38]
Arnesen, T. Towards a functional understanding of protein N-Terminal acetylation. PLoS Biol., 2011, 9(5)e1001074
[39]
Forte, G.M.; Pool, M.R.; Stirling, C.J. N-terminal acetylation inhibits protein targeting to the endoplasmic reticulum. PLoS Biol., 2011, 9(5)e1001073
[40]
Sandomenico, A.; Russo, A.; Palmieri, G.; Bergamo, P.; Gogliettino, P.; Falcigno, L.; Ruvo, M. Small peptide inhibitors of acetyl-peptide hydrolase having an uncommon mechanism of inhibition and a stable bent conformation. J. Med. Chem., 2012, 55(5), 2102-2111.
[41]
Fujino, T.; Watanabe, K.; Beppu, M.; Kikugawa, K.; Yasuda, H. Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase. Biochim. Biophys. Acta, 2000, 1478(1), 102-112.
[42]
Shimizu, K.; Fujino, T.; Ando, K.; Hayakawa, M.; Yasuda, H.; Kikugawa, K. Overexpression of oxidized protein hydrolase protects COS-7 cells from oxidative stress-induced inhibition of cell growth and survival. Biochem. Biophys. Res. Commun., 2003, 304(4), 766-771.
[43]
Adibekian, A.; Martin, B.R.; Wang, C.; Hsu, K.L.; Bachovchin, D.A.; Niessen, S.; Hoover, H.; Cravatt, B.F. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat. Chem. Biol., 2011, 7(7), 469-478.
[44]
Zeng, Z.; Rulten, S.L.; Breslin, C.; Zlatanou, A.; Coulthard, V.; Caldecott, K.W. Acylpeptide hydrolase is a component of the cellular response to DNA Damage. DNA Repair, 2017, 58, 52-61.
[45]
Erlandsson, R.; Boldog, F.; Persson, B.; Zabarovsky, B.; Allikmets, R.L.; Sümegi, J.; Klein, G.; Jörnvall, H. The gene from the short arm of chromosome 3, at D3F15S2, frequently deleted in renal cell carcinoma, encodes acylpeptide hydrolase. Oncogene, 1991, 6, 1293-1295.
[46]
Fage, C.D.; Hegemann, J.D.; Nebel, A.J.; Steinbach, R.M.; Zhu, S.; Linne, U.; Harms, K.; Bange, G.; Marahiel, M.A. Structure and mechanism of the Sphingopyxin I lasso peptide isopeptidase. Angew. Chem. Int. Ed. Engl., 2016, 55(41), 12717-12721.
[47]
Rawlings, N.D.; Barrett, A.J. Evolutionary families of peptidases. Biochem. J., 1993, 290(1), 205-218.
[48]
Liu, F.; Zhao, Z.S.; Ren, Y.; Cheng, G.; Tang, X.F.; Tang, B. Autocatalytic activation of a thermostable glutamyl endopeptidase capable of hydrolyzing proteins at high temperatures. Appl. Microbiol. Biotechnol., 2016, 100(24), 10429-10441.
[49]
Ohara-Nemoto, Y.; Ikeda, Y.; Kobayashi, M.; Sasaki, M.; Tajika, S.; Kimura, S. Characterization and molecular cloning of a glutamyl endopeptidase from Staphylococcus epidermidis. Microb. Pathog., 2002, 33(1), 33-41.
[50]
Calander, A.M.; Dubin, G.; Potempa, J.; Tarkowski, A. Staphylococcus aureus infection triggers production of neutralizing, V8 protease-specific antibodies. FEMS Immunol. Med. Microbiol., 2008, 52(2), 267-272.
[51]
Qin, X.; Singh, K.V.; Weinstock, G.M.; Murray, B.E. Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. Infect. Immun., 2000, 68(5), 2579-2586.
[52]
Lee, C.W.; Yang, I.S. Cutaneous calcinosis in erythromelanosis follicularis faciei et colli. Clin. Exp. Dermatol., 1987, 12(1), 31-32.
[53]
O’Toole, P.W.; Foster, T.J. Nucleotide sequence of the epidermolytic toxin A gene of Staphylococcus aureus. J. Bacteriol., 1987, 169(9), 3910-3915.
[54]
Dancer, S.; Garratt, R.; Saldanha, J.; Jhoti, H.; Evans, R. The epidermolytic toxins are serine proteases. FEBS Lett., 1990, 268(1), 129-132.
[55]
Bukowski, M.; Wladyka, B.; Dubin, G. Exfoliative toxins of Staphylococcus aureus. Toxins, 2010, 2(5), 1148-1165.
[56]
Nemoto, T. K.; Ohara-Nemoto, Y.; Bezerra, G.A.; Shimoyama, Y.; Kimura, S. A Porphyromonas gingivalis periplasmic novel exopeptidase, acylpeptidyl oligopeptidase, releases N-acylated di- and tripeptides from oligopeptides. J. Biol. Chem., 2016, 291(11), 5913-5925.
[57]
Nishimura, M.; Ikeda, K.; Sugiyama, M. Molecular cloning and characterization of gene encoding novel puromycin-inactivating enzyme from blasticidin S-producing Streptomyces morookaensis. J. Biosci. Bioeng., 2006, 101(1), 63-69.
[58]
Matoba, Y.; Nakayama, A.; Oda, K.; Noda, M.; Kumagai, M.; Nishimura, M.; Sugiyama, M. Structural evidence that puromycin hydrolase is a new type of aminopeptidase with a prolyl oligopeptidase family fold. Proteins, 2011, 79(10), 2999-3005.
[59]
Fülöp, V.; Böcskei, Z.; Polgár, L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell, 1998, 94(2), 161-170.
[60]
McLuskey, K.; Paterson, N.G.; Bland, N.D.; Isaacs, N.W.; Mottram, J.C. Crystal structure of Leishmania major oligopeptidase B gives insight into the enzymatic properties of a trypanosomatid virulence factor. J. Biol. Chem., 2010, 285(50), 39249-39259.
[61]
Bartlam, M.; Wang, G.; Yang, H.; Gao, R.; Zhao, X.; Xie, G.; Cao, S.; Feng, Y.; Rao, Z. Crystal structure of an acylpeptide hydrolase/esterase from Aeropyrum pernix K1. Structure, 2004, 12(8), 1481-1488.
[62]
Rasmussen, H.B.; Branner, H.B.; Wiberg, F.C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol., 2003, 10(1), 19-25.
[63]
Canning, P.; Rea, D.; Morty, R.E.; Fülöp, V. Crystal structures of Trypanosoma brucei oligopeptidase B broaden the paradigm of catalytic regulation in prolyl oligopeptidase family enzymes. PLoS One, 2013, 8(11)e79349
[64]
Motta, F.N.; Bastos, I.M.; Faudry, E.; Ebel, C.; Lima, M.M.; Neves, D.; Ragno, M.; Barbosa, J.A.; de Freitas, S.M.; Santana, J.M. The Trypanosoma cruzi virulence factor oligopeptidase B (OPBTc) assembles into an active and stable dimer. PLoS One, 2012, 7(1)e30431
[65]
Fukumoto, J.; Ismail, N.I.; Kubo, M.; Kinoshita, K.; Inoue, M.; Yuasa, K.; Nishimoto, M.; Matsuki, H.; Tsuji, A. Possible role of inter-domain salt bridges in oligopeptidase B from Trypanosoma brucei: Critical role of Glu172 of non-catalytic b-propeller domain in catalytic activity and Glu490 of catalytic domain in stability of OPB. J. Biochem., 2013, 154(5), 465-473.
[66]
Papaleo, E.; Paravicini, F.; Grandori, R.; De Gioia, L.; Brocca, S. Structural investigation of the cold-adapted acylaminoacyl peptidase from Sporosarcina psychrophila by atomistic simulations and biophysical methods. Biochim. Biophys. Acta, 2014, 1844(12), 2203-2213.
[67]
Szeltner, Z.; Kiss, A.L.; Domokos, K.; Harmat, V.; Náray-Szabó, G.; Polgár, L. Characterization of a novel acylaminoacyl peptidase with hexameric structure and endopeptidase activity. Biochim. Biophys. Acta, 2009, 1794(8), 1204-1210.
[68]
Mitta, M.; Asada, K.; Uchimura, Y.; Kimizuka, F.; Kato, I.; Sakiyama, F.; Tsunasawa, S. The primary structure of porcine liver acylamino acid-releasing enzyme deduced from cDNA sequences. J. Biochem., 1989, 106(4), 548-551.
[69]
Wright, H.; Kiss, A.L.; Szeltner, Z.; Polgár, L.; Fülöp, V. Crystallization and preliminary crystallographic analysis of porcine acylaminoacyl peptidase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2005, 61(10), 942-944.
[70]
Fuxreiter, M.; Magyar, C.; Juhász, T.; Szeltner, Z.; Polgár, L.; Simon, I. Flexibility of prolyl oligopeptidase: molecular dynamics and molecular framework analysis of the potential substrate pathways. Proteins, 2005, 60(3), 504-512.
[71]
Menyhárd, D.K.; Kiss-Szemán, A.; Tichy-Rács, É.; Hornung, B.; Rádi, K.; Szeltner, Z.; Domokos, K.; Szamosi, I.; Náray-Szabó, G.; Polgár, L.; Harmat, V. A self-compartmentalizing hexamer serine protease from Pyrococcus horikoshii: Substrate selection achieved through multimerization. J. Biol. Chem., 2013, 288(24), 17884-17894.
[72]
Kaszuba, K. Rog. T.; St Pierre. J.F.; Mannisto. P.T.; Karttunen. M.; Bunker, A. Molecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity. SAR QSAR Environ. Res., 2009, 20(7-8), 595-609.
[73]
Juhász, T.; Szeltner, Z.; Polgár, L. Truncated prolyl oligopeptidase from Pyrococcus furiosus. Proteins, 2007, 69(3), 633-643.
[74]
Menyhárd, D.K.; Orgován, Z.; Szeltner, Z.; Szamosi, I.; Harmat, V. Catalytically distinct states captured in a crystal lattice: The substrate-bound and scavenger states of acylaminoacyl peptidase and their implications for functionality. Acta Crystallogr. D Biol. Crystallogr., 2015, 71(3), 461-472.
[75]
Richardson, J.S.; Richardson, D.C. Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc. Natl. Acad. Sci. USA, 2002, 99(5), 2754-2759.
[76]
Maurer-Stroh, S.; Debulpaep, M.; Kuemmerer, N.; de la Paz Lopez, M.; Martins, I.C.; Reumers, J.; Morris, K.L.; Copland, A.; Serpell, L.; Serrano, L.; Schymkowitz, J.W.; Rousseau, F. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat. Methods, 2010, 7, 237-242.
[77]
Krissinel, E.; Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol., 2007, 372(3), 774-797.
[78]
Szeltner, Z.; Rea, D.; Juhász, T.; Renner, V.; Fülöp, V.; Polgár, L. Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding. J. Mol. Biol., 2004, 340, 627-637.
[79]
Shan, L.; Mathews, I.I.; Khosla, C. Structural and mechanistic analysis of two prolyl endopeptidases: Role of interdomain dynamics in catalysis and specificity. Proc. Natl. Acad. Sci. USA, 2005, 102(10), 3599-3604.
[80]
Czekster, C.M.; Ludewig, H.; McMahon, S.A.; Naismith, J.H. Characterization of a dual function macrocyclase enables design and use of efficient macrocyclization substrates. Nat. Commun., 2017, 8, 1045.
[81]
Li, M.; Chen, C.; Davies, D.R.; Chiu, T.K. Induced-fit mechanism for prolyl endopeptidase. J. Biol. Chem., 2010, 285(28), 21487-21495.
[82]
Kiss, A.L.; Hornung, B.; Rádi, K.; Gengeliczki, Z.; Sztáray, B.; Juhász, T.; Szeltner, Z.; Harmat, V.; Polgár, L. The acylaminoacyl peptidase from Aeropyrum pernix K1 thought to be an exopeptidase displays endopeptidase activity. J. Mol. Biol., 2007, 368(2), 509-520.
[83]
Kiss, A.L.; Palló, A.; Náray-Szabó, G.; Harmat, V.; Polgár, L. Structural and kinetic contributions of the oxyanion binding site to the catalytic activity of acylaminoacyl peptidase. J. Struct. Biol., 2008, 162(2), 312-323.
[86]
Han, Q.; Robinson, H.; Li, J. Biochemical identification and crystal structure of kynurenine formamidase from Drosophila melanogaster. Biochem. J., 2012, 446(2), 253-260.
[87]
Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J.C.; Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem., 2003, 278(42), 41141-41147.
[88]
Terzyan, S.; Wang, C.S.; Downs, D.; Hunter, B.; Zhang, X.C. Crystal structure of the catalytic domain of human bile salt activated lipase. Protein Sci., 2000, 9(9), 1783-1790.
[89]
Fabrichny, I.P.; Leone, P.; Sulzenbacher, G.; Comoletti, D.; Miller, M.T.; Taylor, P.; Bourne, Y.; Marchot, P. Structural analysis of the synaptic protein neuroligin and its beta-neurexin complex: determinants for folding and cell adhesion. Neuron, 2007, 56(6), 979-991.
[90]
Wu, D.; Li, Y.; Song, G.; Zhang, D.; Shaw, N.; Liu, Z.J. Crystal structure of human esterase D: A potential genetic marker of retinoblastoma. FASEB J., 2009, 23(5), 1441-1446.
[92]
Won, S.J.; Davda, D.; Labby, K.J.; Hwang, S.Y.; Pricer, R.; Majmudar, J.D.; Armacost, K.A.; Rodriguez, L.A.; Rodriguez, C.L.; Chong, F.S.; Torossian, K.A.; Palakurthi, J.; Hur, E.S.; Meagher, J.L.; Brooks, C.L. 3rd; Stuckey, J.A.; Martin, B.R. Molecular mechanism for isoform-selective inhibition of acyl protein thioesterases 1 and 2 (APT1 and APT2). ACS Chem. Biol., 2016, 11(12), 3374-3382.
[93]
Mandel, C.R.; Tweel, B.; Tong, L. Crystal structure of human mitochondrial acyl-CoA thioesterase (ACOT2). Biochem. Biophys. Res. Commun., 2009, 385(4), 630-633.